Therapeutic Potential of Direct Clearance of the Amyloid-β in Alzheimer’s Disease
Open Access
- 10 February 2020
- journal article
- research article
- Published by MDPI AG in Brain Sciences
- Vol. 10 (2) , 93
Abstract
Alzheimer’s disease (AD) is characterized by deposition and accumulation of amyloid-β (Aβ) and its corresponding plaques within the brain. Although much debate exists whether these plaques are the cause or the effect of AD, the accumulation of Aβ is linked with the imbalance between the production and clearance of Aβ. The receptor for advanced glycation endproducts (RAGE) facilitates entry of free Aβ from the peripheral stream. Conversely, lipoprotein receptor-related protein 1 (LRP1), located in the abluminal side at the blood–brain barrier mediates the efflux of Aβ. Research on altering the rates of clearance of Aβ by targeting these two pathways has been extensively study. Additionally, a cerebrospinal fluid (CSF) circulation assistant device has also been evaluated as an approach to increase solute concentration in the CSF via mechanical drainage, to allow for removal of Aβ from the brain. Herein, we provide a brief review of these approaches that are designed to re-establish a homeostatic Aβ balance in the brain.Keywords
This publication has 46 references indexed in Scilit:
- Effect of TTP488 in patients with mild to moderate Alzheimer’s diseaseBMC Neurology, 2014
- Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liverProceedings of the National Academy of Sciences, 2012
- PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 2011
- Advanced Glycation End Product Recognition by the Receptor for AGEsStructure, 2011
- Advanced glycation endproducts: from precursors to RAGE: round and round we goAmino Acids, 2010
- RAGE‐dependent signaling in microglia contributes to neuroinflammation, Aβ accumulation, and impaired learning/memory in a mouse model of Alzheimer's diseaseThe FASEB Journal, 2009
- Discovery of amyloid‐beta aggregation inhibitors using an engineered assay for intracellular protein folding and solubilityProtein Science, 2008
- γ-Secretase Limits the Inflammatory Response Through the Processing of LRP1Science Signaling, 2008
- Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease MiceThe Journal of Neuroscience, 2008
- RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brainNature Medicine, 2003